Abstract
The past 25 years have seen unprecedented advancements in the area of women's
health. A number of events have helped to bring the concerns of women's health
to the forefront of medicine but the most significant was the women's health
movement, which increased attention to women's health issues and the
shortcomings of traditional medical practice and research. The National
Institutes of Health, the American Medical Association, and the Office of
Research on Women's Health were all instrumental in affecting changes. Large
studies are now conducted to gather data on the prevention and treatment of
the major causes of death in middle-aged and older women, including cancer and
osteoporosis. A number of societies have been established to bring attention
to serious shortcomings and unmet needs in women's health research worldwide
with the focus on the study of diseases that affect only women and the
secondary influence of reproduction on other physiological systems. Thanks to
insistent congresswomen, women's health activists, pressure from advocacy
groups like the National Women's Health Network and the Public Citizen's
Health Research Group, women's health issues have risen to the public
awareness.
The market for prescription drugs to treat the constellation of conditions
that make up the discipline of women's health has follow right along with the
consciousness raising efforts. Since Kalorama's last edition of this study,
not only have revenues grown almost across all sectors, but the R&D pipeline
has virtually exploded, setting up both great potential for the years ahead
and some difficult competitive challenges.
This report provides market size, growth, and share for the following product
categories:
- Autoimmune diseases
- Cancer
- Gynecological and Sexually Transmitted Diseases
- Hormones
- Osteoporosis
- Urinary Disorders
View Cart
